FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025.
- DOI
- 10.1093/haschl/qxag229
- Published
- 2026 Sep
- Container
- Health affairs scholar
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/haschl/qxag229,
title = {FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025.},
author = {Sun Y and Ballreich J and Acha J and Modi R and Alamdar Yazdi MA and Dada M and Dai T and Anderson G and Socal MP},
year = {2026},
journal = {Health affairs scholar},
doi = {10.1093/haschl/qxag229},
url = {https://doi.org/10.1093/haschl/qxag229}
}RIS
TY - JOUR TI - FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025. AU - Sun Y AU - Ballreich J AU - Acha J AU - Modi R AU - Alamdar Yazdi MA AU - Dada M AU - Dai T AU - Anderson G AU - Socal MP PY - 2026 JO - Health affairs scholar DO - 10.1093/haschl/qxag229 UR - https://doi.org/10.1093/haschl/qxag229 ER -
APA
Y, S., J, B., J, A., R, M., MA, A. Y., M, D., T, D., G, A., & MP, S. (2026). FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025.. Health affairs scholar. https://doi.org/10.1093/haschl/qxag229
Source records
- pubmed · retrieved 2026-11-10T20:42:26.611Z